University of Glasgow spin-out Nebu~Flow has received a Scottish Enterprise grant worth £2 million “to accelerate development and patient access to its patented nebulizer technology in the UK and globally,” the company said. The company received a £1 million award from Innovate UK in 2022 for development of its acoustic wave nebulization technology and closed a £4.7 million investment round in 2024.
According to Nebu-Flow, the new grant will support finalization of the nebulizer design, performance testing, and preparation of regulatory submissions. The company says that it intends to seek approval to market the nebulizer in the US and Europe in addition to the UK.
Nebu-Flow CEO Andrea Cusack commented, “This support from Scottish Enterprise is a huge moment for our team. It allows us to turn years of Scottish research and engineering into a real product that could make a genuine difference to patients’ lives. Our goal is simple: to help people get better, more effective medicines in a way that’s easier, safer and more comfortable for them.”
Scottish Enterprise Director Scaling Innovation Nicola Anderson said, “Scottish Enterprise has nurtured Nebu~Flow’s ambition to revolutionize respiratory drug delivery over a number of years, from inclusion in our Unlocking Ambition entrepreneurship program, feasibility grant support, investment in their vision and now with this significant R&D grant award. The human health sector is a key opportunity area for growth in Scotland. Companies like Nebu~Flow play a vital role in transforming our economy by scaling up, creating high-value jobs and competing internationally. It has been fantastic to follow their journey from university spinout to today where they are poised to bring the technology to market. With this progress, there’s real hope that their work will deliver significant benefits for respiratory patients worldwide.”
Read the Nebu-Flow press release
